TY - JOUR
T1 - Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease
AU - Seemiller, Joseph
AU - Morrow, Christopher
AU - Hinkle, Jared T.
AU - Perepezko, Kate
AU - Kamath, Vidyulata
AU - Pontone, Gregory M.
AU - Mills, Kelly A.
N1 - Publisher Copyright:
© 2024 International Parkinson and Movement Disorder Society.
PY - 2024/5
Y1 - 2024/5
N2 - Background: PD causes striatal dopaminergic denervation in a posterior/dorsal to anterior/ventral gradient, leaving motor and associative cortico-striato-pallido-thalamic loops differentially susceptible to hyperdopaminergic effects with treatment. As the choice and titration of symptomatic PD medications are guided primarily by motor symptoms, it is important to understand their cognitive implications. Objective: To investigate the effects of acute dopaminergic medication administration on executive function in Parkinson's disease (PD). Methods: Participants with idiopathic PD were administered the oral Symbol Digit Modalities Test (SDMT; n = 181) and the Stroop test (n = 172) in the off-medication and “best on” medication states. ANCOVA was used to test for differences between off-medication and on-medication scores corrected for age and years of education. Results: After administration of symptomatic medications, scores worsened on the SDMT (F = 11.70, P < 0.001, d = −0.13), improved on the Stroop color (F = 26.89, P < 0.001, d = 0.184), word (F = 6.25, P = 0.013, d = 0.09), and color-word (F = 13.22, P < 0.001, d = 0.16) test components, and the Stroop difference and ratio-based interference scores did not significantly change. Longer disease duration correlated with lower scores on the SDMT, Stroop color, word, and color-word scores; however, longer disease duration and higher levodopa-equivalents correlated with higher Stroop difference-based interference scores. Conclusions: Symptomatic medication differentially affects performance on two cognitive tests in PD. After acute treatment, core Stroop measures improved, Stroop interference was unchanged, and SDMT performance worsened, likely reflecting complex changes in processing speed and executive function related to acute treatment. When considering motor symptom therapies in PD, an individual's cognitive demands and expectations, especially regarding executive function, should be considered.
AB - Background: PD causes striatal dopaminergic denervation in a posterior/dorsal to anterior/ventral gradient, leaving motor and associative cortico-striato-pallido-thalamic loops differentially susceptible to hyperdopaminergic effects with treatment. As the choice and titration of symptomatic PD medications are guided primarily by motor symptoms, it is important to understand their cognitive implications. Objective: To investigate the effects of acute dopaminergic medication administration on executive function in Parkinson's disease (PD). Methods: Participants with idiopathic PD were administered the oral Symbol Digit Modalities Test (SDMT; n = 181) and the Stroop test (n = 172) in the off-medication and “best on” medication states. ANCOVA was used to test for differences between off-medication and on-medication scores corrected for age and years of education. Results: After administration of symptomatic medications, scores worsened on the SDMT (F = 11.70, P < 0.001, d = −0.13), improved on the Stroop color (F = 26.89, P < 0.001, d = 0.184), word (F = 6.25, P = 0.013, d = 0.09), and color-word (F = 13.22, P < 0.001, d = 0.16) test components, and the Stroop difference and ratio-based interference scores did not significantly change. Longer disease duration correlated with lower scores on the SDMT, Stroop color, word, and color-word scores; however, longer disease duration and higher levodopa-equivalents correlated with higher Stroop difference-based interference scores. Conclusions: Symptomatic medication differentially affects performance on two cognitive tests in PD. After acute treatment, core Stroop measures improved, Stroop interference was unchanged, and SDMT performance worsened, likely reflecting complex changes in processing speed and executive function related to acute treatment. When considering motor symptom therapies in PD, an individual's cognitive demands and expectations, especially regarding executive function, should be considered.
UR - https://www.scopus.com/pages/publications/85187444506
UR - https://www.scopus.com/pages/publications/85187444506#tab=citedBy
U2 - 10.1002/mdc3.14017
DO - 10.1002/mdc3.14017
M3 - Article
C2 - 38470011
AN - SCOPUS:85187444506
SN - 2330-1619
VL - 11
SP - 534
EP - 542
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 5
ER -